Business
Grant of Options
Grant of Options.
About this update from Cizzle Biotechnology Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2821R\n Cizzle Biotechnology Holdings PLC\n 04 November 2021\n \n \n \n \n 4 November 2021\n \n \n Cizzle Biotechnology Holdings Plc\n \n \n (\"Cizzle Biotechnology\" or the \"Company\")\n \n \n \n \n \n Grant of Options\n \n \n Cizzle Biotechnology, the UK based diagnostics developer, announces \n that on 3 November 2021 the Company granted options (\"Options\") over a total of 19,741,345 ordinary shares of 1 pence each in the capital of the Company (\"Ordinary Shares\") to Persons Discharging Managerial Responsibilities (\"PDMRs\") pursuant to the Company's newly established Management Incentive Plan.\n \n \n The intention to establish an option scheme was described in the Company's prospectus published on 23 April 2021 (the \"Prospectus\") and that such a scheme, when put in place, would comply with the guidance issued by The Investment Association.\n \n \n \n Taking into account the commitments made in the Prospectus, the Options have been granted as follows:\n \n \n \n \n \n \n Name\n \n \n \n \n Role\n \n \n \n \n Number of new Options granted\n \n \n \n \n Total number of options held following grant\n \n \n \n \n New Options as percentage of current issued share capital\n \n \n \n \n Total number of Ordinary Shares held\n \n \n \n \n Percentage of current issued share capital held\n \n \n \n \n \n \n Allan Syms\n \n \n \n \n Executive Chairman\n \n \n \n \n 5,068,956\n \n \n \n \n 5,068,956\n \n \n \n \n 2.0%\n \n \n \n \n -\n \n \n \n \n -\n \n \n \n \n \n \n Dawn Coverley\n \n \n \n \n Non-executive Director\n \n \n \n \n 12,672,389\n \n \n \n \n 16,361,485**\n \n \n \n \n 5.0%\n \n \n \n \n 13,359,042*\n \n \n \n \n 5.12%*\n \n \n \n \n \n \n Nigel Lee ***\n \n \n \n \n Finance Director\n \n \n \n \n 2,000,000\n \n \n \n \n 2,001,600\n \n \n \n \n 0.79%\n \n \n \n \n 18,571\n \n \n \n \n 0.007%\n \n \n \n \n \n \n \n \n *this includes 7,055,548 shares held by Professor Dawn Coverley's husband, Justin Ainscough, a founder scientist of Cizzle Biotechnology Ltd.\n \n \n ** the total number of options held by Dawn Coverley following this grant includes 3,689,096 options exercisable within three years from 14 May 2021 at an exercise price of 1.534p per Ordinary Share. The exercise of these options is not subject to any conditions. \n \n \n *** includes 1,600 options and 18,571 sha...